10:02 AM EST - InMed Pharmaceuticals Inc. : Announced that dosing of subjects has begun in its second Phase 1 clinical trial with INM-755. INM-755 is being developed as a topical CBN-based cream to potentially treat Epidermolysis Bullosa as well as potentially other dermatological diseases. InMed Pharmaceuticals Inc.
shares T.IN are trading up $0.02 at $7.45.
